终末期肝病模型-乳酸对慢性肝病患者住院死亡的预测
本研究基于德克萨斯州两个医疗系统2010-2015年慢性肝病患者数据,开发并验证了包含MELD和入院乳酸(LA)的MELD-LA模型,并在14家三级肝病中心的前瞻性队列中进一步验证。MELD-LA对住院死亡具有优秀预测能力(开发队列C统计量0.81,验证队列0.85和0.82),尤其在特定肝硬化诊断或脓毒症患者中表现良好,且较MELD alone改善了23.5%患者的风险预测。
要点
- MELD-LA模型可早期客观预测慢性肝病患者住院死亡。
- MELD评分25时,乳酸1、3、5、>8 mmol/L对应住院死亡率11.2%、19.4%、34.3%、>50%。
- MELD-LA较MELD alone改善23.5%患者的风险预测。
核心结论
- MELD-LA是慢性肝病患者住院死亡的早期客观预测指标,可用于风险评估并指导治疗选择。
研究设计与样本
- 在德克萨斯州两个大型医疗系统2010-2015年慢性肝病患者中开发(n=3,588)和验证(n=1,804)MELD-LA模型。
- 在14家三级肝病中心前瞻性入组的非择期住院肝硬化患者(n=726)中进一步验证。
主要发现
- MELD-LA预测住院死亡的C统计量在开发队列为0.81(95%CI 0.79-0.82),CTX验证队列为0.85(95%CI 0.78-0.87),多中心队列为0.82(95%CI 0.74-0.88)。
- 在特定肝硬化诊断患者中C统计量为0.84(95%CI 0.81-0.86),在脓毒症患者中为0.80(95%CI 0.78-0.82)。
- MELD评分25时,住院死亡率随乳酸升高而增加:LA=1 mmol/L为11.2%,LA=3 mmol/L为19.4%,LA=5 mmol/L为34.3%,LA>8 mmol/L为>50%。
- MELD-LA与器官衰竭数量增加呈线性相关(P < 0.01)。
- 与MELD alone相比,MELD-LA改善了23.5%患者的风险预测。
临床怎么用
- 对于慢性肝病住院患者,可考虑使用MELD-LA模型(bswh.md/meldla)进行早期死亡风险评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Compared to other chronic diseases, patients with chronic liver disease (CLD) have significantly higher inpatient mortality; accurate models to predict inpatient mortality are lacking. Serum lactate (LA) may be elevated in patients with CLD due to both tissue hypoperfusion as well as decreased LA clearance. We hypothesized that a parsimonious model consisting of Model for End-Stage Liver Disease (MELD) and LA at admission may predict inpatient mortality in patients with CLD. APPROACH AND RESULTS: We examined all patients with CLD in two large and diverse health care systems in Texas (North Texas [NTX] and Central Texas [CTX]) between 2010 and 2015. We developed (n = 3,588) and validated (n = 1,804) a model containing MELD and LA measured at the time of hospitalization. We further validated the model in a second cohort of 14 tertiary care hepatology centers that prospectively enrolled nonelective hospitalized patients with cirrhosis (n = 726). MELD-LA was an excellent predictor of inpatient mortality in development (concordance statistic [C-statistic] = 0.81, 95% confidence interval [CI] 0.79-0.82) and both validation cohorts (CTX cohort, C-statistic = 0.85, 95% CI 0.78-0.87; multicenter cohort C-statistic = 0.82, 95% CI 0.74-0.88). MELD-LA performed especially well in patients with specific cirrhosis diagnoses (C-statistic = 0.84, 95% CI 0.81-0.86) or sepsis (C-statistic = 0.80, 95% CI 0.78-0.82). For MELD score 25, inpatient mortality rates were 11.2% (LA = 1 mmol/L), 19.4% (LA = 3 mmol/L), 34.3% (LA = 5 mmol/L), and >50% (LA > 8 mmol/L). A linear increase (P < 0.01) was seen in MELD-LA and increasing number of organ failures. Overall, use of MELD-LA improved the risk prediction in 23.5% of patients compared to MELD alone. CONCLUSIONS: MELD-LA (bswh.md/meldla) is an early and objective predictor of inpatient mortality and may serve as a model for risk assessment and guide therapeutic options.
引用
- Sarmast N, Ogola GO, Kouznetsova M, et al. Model for End-Stage Liver Disease-Lactate and Prediction of Inpatient Mortality in Patients With Chronic Liver Disease. Hepatology. 2020. PMID: 32083761. doi:10.1002/hep.31199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。